0001493152-21-001656 | 10-K | XBRL Viewer

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Oct. 31, 2020	Jan. 15, 2021	Apr. 30, 2020
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-K
Document Period End Date	Oct. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 39,995,271
Entity Common Stock, Shares Outstanding		111,971,688
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Current assets:
Cash and cash equivalents	$ 25,178	$ 32,363
Deferred expenses	1,808	2,353
Prepaid expenses and other current assets	865	1,433
Total current assets	27,851	36,149
Property and equipment (net of accumulated depreciation)	2,393	4,350
Intangible assets (net of accumulated amortization)	3,261	4,575
Operating right-of-use asset (net of accumulated amortization)	4,839
Other assets	182	183
Total assets	38,526	45,257
Current liabilities:
Accounts payable	410	976
Accrued expenses	1,737	3,478
Current portion of operating lease liability	962
Deferred revenue	165
Common stock warrant liability	17	19
Other current liabilities		48
Total current liabilities	3,291	4,521
Operating lease liability, net of current portion	5,055
Other liabilities		1,205
Total liabilities	8,346	5,726
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2020 and 2019. Liquidation preference of $0 at October 31, 2020 and 2019.
Common stock - $0.001 par value; 170,000,000 shares authorized, 78,074,023 and 50,201,671 shares issued and outstanding at October 31, 2020 and 2019.	78	50
Additional paid-in capital	440,840	423,750
Accumulated deficit	(410,738)	(384,269)
Total stockholders' equity	30,180	39,531
Total liabilities and stockholders' equity	$ 38,526	$ 45,257

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	78,074,023	50,201,671
Common stock, shares outstanding	78,074,023	50,201,671

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Revenue	$ 253	$ 20,884
Operating expenses:
Research and development expenses	15,612	26,677
General and administrative expenses	11,090	12,179
Total operating expenses	26,702	38,856
Loss from operations	(26,449)	(17,972)
Other income (expense):
Interest income	110	435
Net changes in fair value of derivative liabilities		2,589
Loss on shares issued in settlement of warrants	(77)	(1,607)
Other expense	(3)	(7)
Net loss before income tax benefit	(26,419)	(16,562)
Income tax expense	50	50
Net loss	$ (26,469)	$ (16,612)
Net loss per common share, basic and diluted	$ (0.43)	$ (1.09)
Weighted average number of common shares outstanding, basic and diluted	61,003,839	15,207,637

Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2018	$ 5	$ 391,703	$ (367,657)	$ 24,051
Balance, shares at Oct. 31, 2018	4,634,189
Stock-based compensation		2,002		2,002
Stock-based compensation, shares	12,220
Tax withholdings paid on equity awards		(15)		(15)
Tax shares sold to pay for tax withholdings on equity awards		14		14
Issuance of shares to employees under ESPP Plan		20		20
Issuance of shares to employees under ESPP Plan, shares	7,435
ESPP Expense		2		2
Pre-funded warrant exercises	$ 13			13
Pre-funded warrant exercises, shares	13,656,000
Warrant exercises	$ 18	104		122
Warrant exercises, shares	17,884,962
Shares issued in settlement of warrants	$ 1	5,462		5,463
Shares issued in settlement of warrants, shares	856,865
Advaxis public offerings	$ 13	24,458		24,471
Advaxis public offerings, shares	13,150,000
Net Loss			(16,612)	(16,612)
Balance at Oct. 31, 2019	$ 50	423,750	(384,269)	39,531
Balance, shares at Oct. 31, 2019	50,201,671
Stock-based compensation		891		891
Stock-based compensation, shares	8,870
Tax withholdings paid on equity awards		(1)		(1)
Tax shares sold to pay for tax withholdings on equity awards		1		1
Issuance of shares to employees under ESPP Plan		7		7
Issuance of shares to employees under ESPP Plan, shares	14,148
ESPP Expense		1		1
Warrant exercises		2		2
Warrant exercises, shares	33,916
Shares issued in settlement of warrants	$ 3	74		77
Shares issued in settlement of warrants, shares	3,000,000
Advaxis public offerings	$ 10	9,618		9,628
Advaxis public offerings, shares	10,000,000
At-the-market shares issued	$ 3	1,435		1,438
At-the-market shares issued, shares	2,489,104
Commitment fee shares issued for equity line	$ 1	643		644
Commitment fee shares issued for equity line, shares	1,084,266
Shares issued under equity line	$ 11	4,419		4,430
Shares issued under equity line, shares	11,242,048
Net Loss			(26,469)	(26,469)
Balance at Oct. 31, 2020	$ 78	$ 440,840	$ (410,738)	$ 30,180
Balance, shares at Oct. 31, 2020	78,074,023

Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statement of Cash Flows - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
OPERATING ACTIVITIES
Net loss	$ (26,469)	$ (16,612)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	891	2,002
Employee stock purchase plan expense	1	3
Gain on change in value of warrants		(2,589)
Loss on shares issued in settlement of warrants	77	1,607
Loss on disposal of property and equipment		344
Loss on write-down of property and equipment	1,060	943
Abandonment of intangible assets	1,725	1,104
Depreciation expense	897	1,097
Amortization of deferred offering costs	644
Amortization expense of intangible assets	337	386
Amortization expense of right-of-use assets	744
Change in operating assets and liabilities:
Accounts receivable		1,664
Prepaid expenses and other current assets	1,113	(103)
Other assets	1	18
Accounts payable and accrued expenses	(2,307)	(7,377)
Deferred revenue	165	(18,665)
Operating lease liabilities	(819)
Other liabilities		50
Net cash used in operating activities	(21,940)	(36,128)
INVESTING ACTIVITIES
Purchase of property and equipment		(54)
Proceeds from disposal of property and equipment		83
Cost of intangible assets	(748)	(1,227)
Net cash used in investing activities	(748)	(1,198)
FINANCING ACTIVITIES
Net proceeds from issuance of common stock and pre-funded warrants	15,496	24,471
Warrant exercises		68
Pre-funded warrant exercises		13
Proceeds from employee stock purchase plan	7	20
Employee tax withholdings paid on equity awards	(1)	(15)
Tax shares sold to pay for employee tax withholdings on equity awards	1	14
Net cash provided by financing activities	15,503	24,571
Net decrease in cash and cash equivalents	(7,185)	(12,755)
Cash and cash equivalents at beginning of year	32,363	45,118
Cash and cash equivalents at end of year	25,178	32,363
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50	50
Supplemental Schedule of Noncash Investing and Financing Activities
Shares issued in settlement of warrants	77	5,463
Warrant liability reclassified into equity		54
Reclass of security deposit to property and equipment for delivered equipment		79
Commitment fee shares issued for equity line	644
Cashless exercise of warrants	$ 2

Nature of Operations and Basis of Presentation

12 Months Ended

Oct. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Basis of Presentation

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Liquidity and Managements Plans

The Company has not yet commercialized any human products and the products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern.

Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants and interest income. From October 2013 through October 2020, the Company raised approximately $309.4 million in gross proceeds ($17.2 million in fiscal year 2020) from various public and private offerings of its common stock.

As of October 31, 2020, the Company had approximately $25.2 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least January 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past several months, the Company has taken steps to obtain additional financing, including the at-the-market (“ATM”) program and the equity line with Lincoln Park Capital. Due to the current state of the Company’s stock price and general market conditions, these programs have not been utilized to the fullest extent, thereby resulting in lower capital availability than anticipated. Management’s plans to mitigate an expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategic or financing investors. The Company was able to raise additional funds subsequent to year end more fully described in the subsequent events footnote (Note 15). The Company has reduced its operating expenses to $26.7 million for the fiscal year ended October 31, 2020 as compared to $38.9 million during the comparable prior period. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing. Therefore, such conditions of substantial doubt as of October 31, 2020 have subsequently been alleviated.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

Summary of Significant Accounting Policies

12 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), determining the Incremental Borrowing Rate (“IBR”) for calculating Right-Of-Use (“ROU”) assets and lease liabilities, deferred expenses, deferred revenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.

Revenue Recognition

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into licensing agreements that are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.

Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Exclusive Licenses. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a performance obligation is distinct from the other performance obligations, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a performance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the value of the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that could provide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation. For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods.

Research and Development Services. The performance obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts.

Milestone Payments. At the inception of each arrangement that includes research or development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. An output method is generally used to measure progress toward complete satisfaction of a milestone. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties. For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

Collaborative Arrangements

The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606. Amounts that are owed to collaboration partners are recognized as an offset to collaboration revenue as such amounts are incurred by the collaboration partner. For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above under ASC 606.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $24.1 million is subject to credit risk at October 31, 2020. The Company has not experienced any losses in such accounts.

Deferred Expenses

Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.

Property and Equipment

Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years.

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned.

Impairment of Long-Lived Assets

The Company periodically assesses the carrying value of intangible and other long-lived assets, and whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. The assets are considered to be impaired if the Company determines that the carrying value may not be recoverable based upon its assessment, which includes consideration of the following events or changes in circumstances:

	●	the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
	●	loss of legal ownership or title to the asset(s);
	●	significant changes in the Company’s strategic business objectives and utilization of the asset(s); and
	●	the impact of significant negative industry or economic trends.

If the assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fair value is determined by the application of discounted cash flow models to project cash flows from the assets. In addition, the Company bases estimates of the useful lives and related amortization or depreciation expense on its subjective estimate of the period the assets will generate revenue or otherwise be used by it. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less selling costs. The Company also periodically reviews the lives assigned to long-lived assets to ensure that the initial estimates do not exceed any revised estimated periods from which the Company expects to realize cash flows from its assets.

Leases

Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases.

At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew.

Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share (as of October 31, 2020, 327,338 warrants are included in the basic earnings per share computation because the exercise price is $0, and as of October 31, 2019, 13,079,000 pre-funded warrants are included in the basic earnings per share computation because the exercise price is nominal):

	As of October 31,
	2020		2019
Warrants		398,226		432,142
Stock options		1,011,768		560,490
Restricted stock units		5,556		14,706
Total		1,415,550		1,007,338

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.

Fair Value of Financial Instruments

The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Monte Carlo simulation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

Recent Accounting Standards

In December 2019, the FASB issued authoritative guidance intended to simplify the accounting for income taxes (ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”). This guidance eliminates certain exceptions to the general approach to the income tax accounting model and adds new guidance to reduce the complexity in accounting for income taxes. This guidance is effective for annual periods after December 15, 2020, including interim periods within those annual periods. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.

Recently Adopted Accounting Standards

On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods.

In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less.

As of the November 1, 2019 effective date, the Company had identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s statements of operations or statements of cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Property and Equipment

12 Months Ended

Oct. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following (in thousands):

	October 31,
	2020			2019
Leasehold improvements	$	2,335		$	2,335
Laboratory equipment		1,218			3,405
Furniture and fixtures		744			744
Computer equipment		409			409
Construction in progress		19			83
Total property and equipment		4,725			6,976
Accumulated depreciation and amortization		(2,332	)		(2,626	)
Net property and equipment	$	2,393		$	4,350

Depreciation expense for the years ended October 31, 2020 and 2019 was approximately $0.9 million and $1.1 million, respectively. Disposals of laboratory equipment resulted in losses of approximately $0 and $0.3 million for the years ended October 31, 2020 and 2019, respectively, that was charged to research and development expenses in the statement of operations.

Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the years ended October 31, 2020 and 2019, the Company recorded impairment losses on idle laboratory equipment of $1.1 million and $0.9 million, respectively, that was charged to research and development expenses in the statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets.

Intangible Assets

12 Months Ended

Oct. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets consist of the following (in thousands):

	October 31,
	2020			2019
Patents	$	4,479		$	5,833
License		777			777
Software		117			117
Total intangibles		5,373			6,727
Accumulated amortization		(2,112	)		(2,152	)
Net intangible assets	$	3,261		$	4,575

The expirations of the existing patents range from 2020 to 2040 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of approximately $1.7 million and $1.1 million were abandoned and were charged to general and administrative expenses in the statement of operations for the years ended October 31, 2020 and 2019, respectively. Intangible asset amortization expense that was charged to general and administrative expense in the statement of operations was approximately $0.3 million and $0.4 million for each of the years ended October 31, 2020 and 2019, respectively.

Management has reviewed its intangible assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA ADXS-HER2 and other products that are in development or out-licensed. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding our studies and developing its intellectual property, the Company would likely record an impairment to certain of these assets.

At October 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

2021	$	289
2022		289
2023		289
2024		289
2025		289
Thereafter		1,816
Total	$	3,261

Accrued Expenses

12 Months Ended

Oct. 31, 2020

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses (in thousands):

	October 31,
	2020		2019
Salaries and other compensation	$	737	$	158
Vendors		671		3,194
Professional fees		329		126
Total accrued expenses	$	1,737	$	3,478

Common Stock Purchase Warrants and Warrant Liability

12 Months Ended

Oct. 31, 2020

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		359,838	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		72,279	September 2024	September 2018 Public Offering
	Grand Total		432,142

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Issued		31,885,500			-
Exercised *		(31,540,962	)		-
Exchanged		(856,865	)		0.37
Expired		(166	)		56.25
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069
Issued		5,000,000			1.25
Exercised **		(33,916	)		0.02
Exchanged		(5,000,000	)		1.25
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640

* Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.

** Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At October 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet.

Shares Issued in Settlement of Equity Warrants

On October 16, 2020, the Company entered into private exchange agreements with certain holders of warrants issued in connection with the Company’s January 2020 public offering of common stock and warrants. The warrants being exchanged provide for the purchase of up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $1.25 per share. The warrants became exercisable on July 21, 2020 and have an expiration date of July 21, 2025. Pursuant to such exchange agreements, the Company agreed to issue 3,000,000 shares of common stock to the investors in exchange for the warrants. The fair value of these warrants approximated the fair value of shares issued in the exchange for these warrants. The Company used the closing stock price to value the shares and Black Scholes model to value these warrants on the date of the exchange. In determining the fair warrant of the warrants issued on October 16, 2020, the Company used the following inputs in its Black-Sholes model: exercise price $1.25, stock price $0.406, expected term 4.76 years, volatility 101.18% and risk-free interest rate 0.32%. In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $77 thousand as the fair value of the shares issued exceeded the fair value of warrants exchanged.

Shares Issued in Settlement of Liability Warrants

On March 14, 2019, the Company entered into private exchange agreements with certain holders of warrants issued in connection with the Company’s September 2018 public offering of common stock and warrants. The warrants being exchanged provided for the purchase of up to an aggregate of 856,865 shares of the Company’s common stock at an exercise price of $22.50, with an expiration date of September 11, 2024. Pursuant to such exchange agreements, the Company issued 856,865 shares of common stock to the investors in exchange for such warrants on a 1:1 basis. The exchange of warrants for common stock caused the down round provision to be triggered for the first time and the exercise price of the warrants that were not exchanged were reduced from $22.50 to $4.50. The warrants were valued at approximately $3.9 million on the March 14, 2019 using the Monte Carlo simulation model. In determining the fair warrant of the warrants issued on March 14, 2019, the Company used the following inputs in its Monte Carlo simulation model: exercise price $22.50, stock price $6.45, expected term 5.50 years, volatility 96.37% and risk-free interest rate 2.44%. In connection with the exchange of warrants for common stock, the Company recorded a loss of approximately $1.6 million as the fair value of the shares issued exceeded the fair value of warrants exchanged.

Warrant Liability

At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants). At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion.

As of October 31, 2020, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

At October 31, 2020 and October 31, 2019, the fair value of the warrant liability was approximately $17,000 and $19,000, respectively. For the years ended October 31, 2020 and 2019, the Company reported income of approximately $0 and $2.6 million, respectively, due to changes in the fair value of the warrant liability.

In measuring the warrant liability, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2020			October 31, 2019
Exercise Price	$	0.37		$	0.37
Stock Price	$	0.34		$	0.32
Expected Term		3.87 years			4.87 years
Volatility %		105.58	%		100.99	%
Risk Free Rate		0.29	%		1.51	%

Share Based Compensation

12 Months Ended

Oct. 31, 2020

Share-based Payment Arrangement [Abstract]

Share Based Compensation

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2020 and 2019 (in thousands):

	Year Ended October 31,
	2020		2019
Research and development	$	308	$	1,036
General and administrative		583		966
Total	$	891	$	2,002

Amendments

The Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholders on May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of common stock that may be issued under the 2015 Plan is 240,000 shares, plus a number of additional shares (not to exceed 43,333) underlying awards outstanding as of the effective date of the 2015 Plan under the prior plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason.

At the Annual Meeting of Stockholders of the Company held on February 21, 2019, the Company’s stockholders voted to approve an amendment to increase the number of authorized shares of common stock from 95,000,000 to 170,000,000 and also voted to approve an amendment to allow the Company to execute a reverse stock split of common stock at the discretion of the Board of Directors. The amendment to increase the number of authorized shares of common stock became effective upon filing of the amendment with the Secretary of State of the State of Delaware on February 28, 2019. Additionally, on March 29, 2019, the Company executed a 1 for 15 reverse stock split. On January 1, 2020, 166,667 shares were added to the 2015 Plan.

At the Annual Meeting of Stockholders of the Company held on May 4, 2020, the Company’s stockholders voted to approve an amendment to increase the number of shares authorized for issuance under the 2015 Plan from 877,744 shares to 6,000,000 shares.

As of October 31, 2020, there were 4,856,116 shares available for issuance under the 2015 Plan.

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the fiscal year ended October 31, 2020 and 2019 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Unvested as of October 31, 2018		32,614		$	70.41
Vested		(12,257	)		78.41
Cancelled		(5,651	)		112.39
Unvested as of October 31, 2019		14,706		$	47.62
Vested		(8,870	)		60.59
Cancelled		(280	)		98.80
Unvested as of October 31, 2020		5,556		$	24.32

The fair value of the RSUs as of the respective vesting dates was approximately $5,000 and $51,000 for the years ended October 31, 2020 and 2019, respectively.

As of October 31, 2020, there was approximately $64,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 0.47 years.

As of October 31, 2020, the aggregate intrinsic value of non-vested RSUs was approximately $2,000.

Employee Stock Awards

Common stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 8,870 shares and 12,245 shares during the years ended October 31, 2020 and 2019, respectively. Total stock compensation expense associated with these awards for the years ended October 31, 2020 and 2019 was approximately $0.2 million and $0.8 million, respectively.

Stock Options

A summary of changes in the stock option plan for the years ended October 31, 2020 and 2019 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2018		330,071		$	122.79		6.56	$	-
Granted		265,882			2.36
Cancelled or expired		(35,463	)		29.52
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Granted		645,000			0.61
Cancelled or expired		(193,722	)		34.47
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Vested and exercisable at October 31, 2020		307,467		$	105.69		4.91	$	1

The following table summarizes information about the outstanding and exercisable options at October 31, 2020:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		746,579		9.41	$	1.10	$	1		68,655		8.67	$	2.62	$	-
$	10.01-$100.00		102,951		7.23	$	28.77	$	-		76,574		7.16	$	29.67	$	-
$	100.01-$200.00		92,847		2.76	$	166.04	$	-		92,847		2.76	$	166.04	$	-
$	200.01-$277.50		69,391		1.58	$	210.79	$	-		69,391		1.58	$	210.79	$	-

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s common stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating expected lives of the options. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2020			October 31, 2019
Expected term	5.50-6.50 years			5.50-6.51 years
Expected volatility		100.27-105.21	%		90.24-104.99	%
Expected dividends		0	%		0	%
Risk free interest rate		0.36-0.62	%		1.35-3.15	%

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the years ended October 31, 2020 and 2019 was approximately $0.7 million and $1.2 million, respectively.

During the fiscal year ended October 31, 2020, 645,000 options were granted with a total grant date fair value of approximately $0.3 million. During the fiscal year ended October 31, 2019, 265,882 options were granted with a total grant date fair value of approximately $0.5 million.

As of October 31, 2020, there was approximately $0.6 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.50 years.

Employee Stock Purchase Plan

The Advaxis, Inc. 2018 Employee Stock Purchase Plan (ESPP) was approved by the Company’s shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’s Common stock are reserved for issuance under the 2018 ESPP.

During the fiscal year ended October 31, 2020, 14,148 shares were issued under the 2018 ESPP and the Company recorded an expense of approximately $1,000. During the fiscal year ended October 31, 2019, 7,435 shares were issued under the 2018 ESPP and the Company recorded an expense of approximately $2,000.

As of October 31, 2020, 976,517 shares of Company’s common stock remain available for issuance under the 2018 ESPP.

Collaboration and Licensing Agreements

12 Months Ended

Oct. 31, 2020

Business Combinations [Abstract]

Collaboration and Licensing Agreements

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agrees to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieves its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis will initiate the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

Provided that OST meets its ongoing obligation to make its Monthly Payments to Advaxis for six consecutive months, Advaxis agrees to transfer, and OST agrees to take full ownership of, the IND application for ADXS31-164 in its entirety to OST, along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development. Until OST makes its Monthly Payments to Advaxis for six consecutive months, Advaxis will continue to bear the costs of the regulatory filing services related to the IND application for ADXS31-164.

Within five business days of achieving the funding milestone of $2,337,500 for the performance of the Children’s Oncology Group study (knowns as the “License Commencement Date”), OST will make a non-refundable and non-creditable payment to Advaxis of $1,550,000 less the cumulative Monthly Payments previously made (the “License Commencement Payment”). Within five days following the License Commencement Date, Advaxis will provide existing drug supply “as is” to OST, and until the drug supply is supplied to OST, Advaxis will bear the storage costs for the drug product. Pursuant to the agreement, the Company is also to receive sales-based milestone payments and royalties on future product sales. In addition, the Company and OST will establish a Joint Steering Committee to oversee the R&D activities.

The promises to (1) Maintain the HER2 product until transfer to OST, (2) Provide the IND application ownership for ADX321-164 to OST, (3) Participate in the Joint Steering Committee, (4) Transfer of IP & licensing rights of ADXS31-164 and related Patents, and (5) Provide Clinical Drug Supply represent one combined performance obligation for revenue recognition purposes. The Company concluded that the transfer of the IP and licensing rights provides OST with a functional, or “right to use,” license, and thus the Company will recognize the upfront fees of $1,550,000 from the license at a point in time. The revenue from the transfer of the license cannot be recognized until the transfer of the corresponding IP to OST has occurred and OST has the ability to benefit from the right to use the license. As the right to use the license begins when OST makes the upfront payment within five days of the License Commencement Date and the IP transfers to OST at that time, the upfront fees from the license will be recognized upon the transfer of the intellectual property to OST.

Since OST is making $25,000 monthly payments that will be creditable against the $1,550,000, as well as additional upfront payments not specified in the contract, the Company will receive payments prior to the performance of the single distinct performance obligation. Due to this, the Company will defer any of the monthly payments until the IP and licensing rights are transferred to OST. However, if OST terminates the contract, which they are able to do with 60-day notice, the Company would recognize any of the payments received when the contract terminates. As of October 31, 2020, OST has made payments totaling $164,653 and this has been recorded as other liabilities in the balance sheet.

Amgen

On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a then- preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize ADXS-NEO. Amgen made an upfront payment to Advaxis of $40 million and purchased directly from Advaxis 203,163 shares of the Company’s common stock, at approximately $123.00 per share (representing a purchase at market using a 20 day VWAP methodology) for a total of $25 million. Amgen assisted in funding the clinical development and commercialization of ADXS-NEO and Advaxis retained manufacturing responsibilities. Advaxis and Amgen collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis received reimbursements for research and development costs and Advaxis was eligible to receive future contingent payments based on development, regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based on worldwide sales by Amgen.

The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Amgen, is a customer. The Company identified the following material promises under the arrangement: (1) licenses, (2) research and development activities, (3) clinical supplies, (4) regulatory responsibilities and (5) participation on a Joint Steering Committee (JSC). The Company determined that the licenses and research and development activities were not distinct from another, as the licenses had limited value without the performance of the research and development activities. Participation on the JSC to oversee the research and development activities was determined to be quantitatively and qualitatively immaterial and therefore was excluded from performance obligations. The clinical supply and regulatory responsibilities did not represent separate performance obligations based on their dependence on the research and development efforts. Based on this assessment, the Company identified one performance obligation at the outset of the Amgen Agreement, which consists of: (1) licenses, (2) research and development activities, (3) clinical supplies and (4) regulatory responsibilities.

Under the Amgen Agreement, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $40 million constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which is allocated to the single performance obligation. The Company concluded that a time-based method was most appropriate to measuring progress toward completion given that the research and development services are satisfied reasonably evenly over the agreement and the Company has a stand-ready obligation to perform over such time. Accordingly, progress toward completion and related revenue recognition is measured using the input method of time elapsed relative to the estimated timeline for Advaxis to submit the Phase 2 package to Amgen, or perform the contractual research and development services, which was the predominant promise in the Company’s combined performance obligation to Amgen.

The reimbursement for the research and development costs was variable consideration that was included in the transaction price at the outset, subject to the constraint. The Company estimated the consideration from the reimbursement of the research and development costs using the most-likely amount. When the research and development costs are no longer constrained, they are added to the transaction price for the single, combined performance obligation and recognized over the same recognition period as the rest of the performance obligation’s allocated revenue. The potential milestone and sales-based royalty payments that the Company was eligible to receive were excluded from the transaction price, as all milestone and sales royalty amounts were fully constrained based on the probability of achievement. The Company reevaluated the transaction price at the end of each reporting period and as uncertain events were resolved or other changes in circumstances occurred, and, as necessary, adjusted its estimate of the transaction price.

On December 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination became effective as of February 8, 2019, and the Company regained worldwide rights for the development and commercialization of its ADXS-NEO program. On October 24, 2019, Advaxis announced that it has enrolled its last patient in its ADXS-NEO program in monotherapy and will not enter Part B.

The remaining deferred revenue of approximately $18.2 million on December 10, 2018 related to the $40 million non-refundable, up-front payment received from Amgen was accounted for as of the modification date. As of that notification date, the Company adjusted revenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation based on the modified service period up to and through the contract termination date of February 8, 2019. The Company recognized cumulative catch-up revenue of approximately $15.6 million on December 10, 2018. The remaining $2.6 million was recognized over the subsequent 60 days until the performance obligation was satisfied on February 8, 2019.

During the years ended October 31, 2020 and 2019, the Company recognized revenue from the Amgen Agreement of approximately $0 and $20.6 million, respectively. During the years ended October 31, 2020 and 2019, the Company received reimbursement of research and development costs of approximately $0 and $2.0 million, which was included in revenue.

Merck& Co., Inc.

On August 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties collaborated on a Phase 1/2 dose-determination and safety trial. The Phase 1 portion of the trial evaluated the safety of our Lm -LLO based immunotherapy for prostate cancer, ADXS-PSA (the “Advaxis Compound”) as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, (the “Merck Compound”) and has determined a recommended Phase 2 combination dose. The Phase 2 portion evaluated the safety and efficacy of the Advaxis Compound in combination with the Merck Compound. Both phases of the trial were in patients with previously treated metastatic castration-resistant prostate cancer. The last patient was dosed in August 2019 and the Company is in the surveillance stage of the study. A joint development committee, comprised of equal representatives from both parties, is responsible for coordinating all regulatory and other activities under, and pursuant to, the Merck Agreement.

Each party is responsible for their own internal costs and expenses to support the trial, while the Company was responsible for all third-party costs of conducting the trial. Merck was responsible for manufacturing and supplying the Merck Compound. The Company was responsible for manufacturing and supplying the Advaxis Compound. The Company is the sponsor of the trial and holds the IND related to the trial.

All data and results generated under the trial (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of Advaxis. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck.

During the each of the years ended October 31, 2020 and 2019, the Company incurred approximately $0.9 million in expenses pertaining to the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations.

Elanco Animal Health (formerly Aratana Therapeutics)

On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue during the fiscal year ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement.

During the fiscal year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the years ended October 31, 2020 and 2019, Advaxis recognized royalty revenue totaling approximately $3,000 and $8,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”) whereby Elanco will be the majority shareholder in Aratana. On October 6, 2020, the Company received a notice from Aratana, dated September 17, 2020, indicating that Aratana was terminating the Exclusive License Agreement effective December 21, 2020. The Company did not incur any early termination penalties as a result of the termination. Aratana was required to make all payments to the Company that were otherwise payable under the Exclusive License Agreement through the effective date of termination.

Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (GBP), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the years ended October 31, 2020 and 2019, the Company recorded $0.25 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

Commitments and Contingencies

12 Months Ended

Oct. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Stendhal

On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest.

From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted. On April 1, 2020, the Arbitrator issued a final award denying Stendhal’s claim in full. The Arbitrator found that the Company had not repudiated the Agreement and did not owe Stendhal damages, fees, or interest associated with the arbitration. The Arbitrator also denied the Company’s claim that Stendhal breached its obligations to the Company. The parties were ordered to bear their own attorneys’ fees and evenly split administrative fees and expenses for the arbitration.

Leases

12 Months Ended

Oct. 31, 2020

Leases [Abstract]

Leases

10. LEASES

Operating Leases

The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the balance sheet.

The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:

	●	As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease.

	●	Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.

	●	Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.

	●	Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability.

Supplemental balance sheet information related to leases as of October 31, 2020 was as follows (in thousands):

Operating Leases:
Operating lease right-of-use assets	$	4,839

Operating lease liability	$	962
Operating lease liability, net of current portion		5,055
Total operating lease liabilities	$	6,017

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Year Months Ended October 31, 2020
Operating lease cost	General and administrative	$	1,158
Short-term lease cost	General and administrative		320
Variable lease cost	General and administrative		547
Total lease expense		$	2,025

Other information related to leases where the Company is the lessee is as follows:

For the Fiscal Year

Ended
October 31, 2020

Weighted-average remaining lease term

5.1 years

Weighted-average discount rate

6.5

Supplemental cash flow information related to operating leases was as follows:

For the Fiscal Year

Ended
October 31, 2020

Cash paid for operating lease liabilities

1,233

Future minimum lease payments under non-cancellable leases as of October 31, 2020 were as follows:

Fiscal Year ending October 31,
2021	$	1,318
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total minimum lease payments		7,065
Less: Imputed interest		(1,048	)
Total	$	6,017

Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands):

Fiscal Year ending October 31,
2021	$	1,318
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total	$	7,065

Under ASC 840, rent expense for the fiscal year ended October 31, 2019 was approximately $1.2 million.

Income Taxes

12 Months Ended

Oct. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

11. INCOME TAXES

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2020			October 31, 2019
Federal
Current	$	-		$	-
Deferred		(4,578	)		32,673
State and Local
Current		-			-
Deferred		(1,445	)		(1,634	)
Change in valuation allowance		6,023			(31,039	)
Income tax provision (benefit)	$	-		$	-

The Company has U.S. federal net operating loss carryovers (“NOLs”) of approximately $89.4 million and $74.0 million at October 31, 2020 and 2019 respectively, available to offset taxable income which expire beginning in 2023. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. During the years ended October 31, 2020 and 2019, the Company performed a detailed analysis of any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. From the entire federal NOL of $299.2 million as of October 31, 2020, approximately $89.4 million is available for use based on Internal Revenue Code Section 382 analysis. The NOL and the deferred tax asset table below does not include approximately $209.8 million of NOL’s that may expire unused. The Company also has New Jersey State Net Operating Loss carryovers of approximately $137.7 million as of October 31, 2020 available to offset future taxable income through 2040.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance.

The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as other expense in the statement of operations. Penalties would be recognized as a component of general and administrative expenses in the statement of operations.

No interest or penalties on unpaid tax were recorded during the years ended October 31, 2020 and 2019, respectively. As of October 31, 2020 and 2019, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.

The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the fiscal year ended October 31, 2017.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):

	Years Ended
	October 31, 2020			October 31, 2019
Deferred Tax Assets
Net operating loss carryovers	$	28,553		$	22,627
Stock-based compensation		10,132			11,767
Research and development credits		10,742			10,234
Capitalized R&D costs		13,822			13,399
Deferred revenue		-			-
Adoption of ASC 842 – Lease Liability		1,691			-
Other deferred tax assets		224			405
Total deferred tax assets	$	65,164		$	58,432
Valuation allowance		(62,845	)		(56,822	)
Deferred tax asset, net of valuation allowance	$	2,319		$	1,610

Deferred Tax Liabilities
Adoption of ASC 842 – ROU Asset		(1,360	)		-
Patent Cost		(917	)		-
Other deferred tax liabilities		(42	)		(1,610	)
Total deferred tax liabilities	$	(2,319	)	$	(1,610	)
Net deferred tax asset (liability)	$	-		$	-

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2020			October 31, 2019
US Federal statutory rate		21.00	%		21.00	%
State income tax, net of federal benefit		5.48			9.84
Permanent differences		(0.05	)		1.23
Research and development credits		1.73			17.30
Change in valuation allowance		(22.82	)		186.84
§382 Impact on NOL		-			(233.87	)
Stock Option Expirations		(5.33	)		(2.34	)
Income tax (provision) benefit		0.00	%		0.00	%

The statement of operations discloses income tax expense of $50. This is a Taiwan Excise tax of 50 levied in connection with the GPP Revenue.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Stockholders' Equity

12 Months Ended

Oct. 31, 2020

Equity [Abstract]

Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

Public Offerings

In April 2019, the Company issued 2,500,000 shares of the Company’s common stock in a public offering at $4.00 per share, less underwriting discounts and commissions. The net proceeds to the Company from the transaction was approximately $9 million.

In July 2019, the Company closed on an underwritten public offering of 10,650,000 shares of its common stock, pre-funded warrants to purchase 13,656,000 shares of common stock and warrants to purchase up to 17,142,000 shares of common stock for gross proceeds of $17.0 million. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.70, and each pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.699. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $15.5 million.

In January 2020, the Company closed on a public offering of 10,000,000 shares of its common stock at a public offering price of $1.05, for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the period beginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire on the fifth anniversary of the Initial Exercise Date. The warrants contain a change of control provision whereby if the change of control is within the Company’s control, the warrants could be settled in cash based on the Black-Scholes value of the warrants at the option of the warrant holder. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $9.6 million.

In May 2020, the Company entered into a sales agreement related to an ATM equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent. From May 2020 to October 2020, the Company sold 2,489,104 shares of its common stock under the ATM program for $1.583 million, or an average of $0.64 per share, and received net proceeds of $1.531 million, net of commissions of $52,000.

Lincoln Park Purchase Agreement

On July 30, 2020, the Company entered into a Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Over the 36-month term of the Purchase Agreement, the Company has the right, but not the obligation, from time to time, to sell to Lincoln Park up to an aggregate amount of $20,000,000 of shares of common stock, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the “Regular Purchase Share Limit”) of its Common Stock (each such purchase, a “Regular Purchase”). Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company’s common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company’s common stock during the ten trading days prior to the purchase date.

As consideration for entering into the Purchase Agreement, the Company issued 1,084,266 shares of common stock to Lincoln Park as a commitment fee. The shares were valued at approximately $0.6 million and were recorded as deferred offering expenses in the balance sheet. The deferred charges were charged against paid-in capital upon future proceeds from the sale of common stock under the Lincoln Park Purchase Agreement.

From August 2020 to October 2020, Lincoln Park purchased 11,242,048 shares of common stock for gross proceeds of approximately $5.1 million. Approximately $50,000 of legal fees were netted against the gross proceeds.

Fair Value

12 Months Ended

Oct. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value

12. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2020 and October 31, 2019:

October 31, 2020	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	17	$	17

October 31, 2019	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	19	$	19

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	Year Ended October 31,
	2020			2019
Beginning balance	$	19		$	6,517
Shares issued in settlement of warrants		-			(3,856	)
Warrant exercises		(2	)		(53	)
Change in fair value		-			(2,589	)
Ending Balance	$	17		$	19

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Employee Benefit Plan

12 Months Ended

Oct. 31, 2020

Retirement Benefits [Abstract]

Employee Benefit Plan

13. EMPLOYEE BENEFIT PLAN

The Company sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) Plan up to the limit allowed under the Internal Revenue Code. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year. The Company made matching contributions which amounted to approximately $0.1 million and $0.2 million for the years ended October 31, 2020 and 2019, respectively. These amounts were charged to the statement of operations. The employer contributions vest immediately.

Subsequent Events

12 Months Ended

Oct. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

15. SUBSEQUENT EVENTS

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.

Subsequent to year end, warrant holders from the Company’s November 2020 offering exercised 4,610,000 warrants in exchange for 4,610,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of about $1.6 million which were payable upon exercise.

In December 2020 and January 2021, the Company received an aggregate of $1,345,000 from OS Therapies upon achievement of the $1,550,000 funding milestone set forth in the license agreement. For more information on the license agreement with OS Therapies, please see Note 8 – “Collaboration and Licensing Agreements” above.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

Estimates

Estimates

Revenue Recognition

Revenue Recognition

Collaborative Arrangements

Collaborative Arrangements

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.

Concentration of Credit Risk

Concentration of Credit Risk

Deferred Expenses

Deferred Expenses

Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.

Property and Equipment

Property and Equipment

When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible Assets

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

	●	the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
	●	loss of legal ownership or title to the asset(s);
	●	significant changes in the Company’s strategic business objectives and utilization of the asset(s); and
	●	the impact of significant negative industry or economic trends.

Leases

Leases

Net Income (Loss) Per Share

Net Income (Loss) per Share

	As of October 31,
	2020		2019
Warrants		398,226		432,142
Stock options		1,011,768		560,490
Restricted stock units		5,556		14,706
Total		1,415,550		1,007,338

Research and Development Expenses

Research and Development Expenses

Stock Based Compensation

Stock Based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Derivative Financial Instruments

Derivative Financial Instruments

Income Taxes

Income Taxes

Recent Accounting Standards

Recent Accounting Standards

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share

	As of October 31,
	2020		2019
Warrants		398,226		432,142
Stock options		1,011,768		560,490
Restricted stock units		5,556		14,706
Total		1,415,550		1,007,338

Property and Equipment (Tables)

12 Months Ended

Oct. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following (in thousands):

	October 31,
	2020			2019
Leasehold improvements	$	2,335		$	2,335
Laboratory equipment		1,218			3,405
Furniture and fixtures		744			744
Computer equipment		409			409
Construction in progress		19			83
Total property and equipment		4,725			6,976
Accumulated depreciation and amortization		(2,332	)		(2,626	)
Net property and equipment	$	2,393		$	4,350

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets consist of the following (in thousands):

	October 31,
	2020			2019
Patents	$	4,479		$	5,833
License		777			777
Software		117			117
Total intangibles		5,373			6,727
Accumulated amortization		(2,112	)		(2,152	)
Net intangible assets	$	3,261		$	4,575

Schedule of Carrying Value of Intangible Assets

At October 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

2021	$	289
2022		289
2023		289
2024		289
2025		289
Thereafter		1,816
Total	$	3,261

Accrued Expenses (Tables)

12 Months Ended

Oct. 31, 2020

Payables and Accruals [Abstract]

Components of Accrued Expenses

The following table represents the major components of accrued expenses (in thousands):

	October 31,
	2020		2019
Salaries and other compensation	$	737	$	158
Vendors		671		3,194
Professional fees		329		126
Total accrued expenses	$	1,737	$	3,478

Common Stock Purchase Warrants and Warrant Liability (Tables)

12 Months Ended

Oct. 31, 2020

Common Stock Purchase Warrants And Warrant Liability

Schedule of Outstanding Warrants

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Summary of Warrants
$	-		359,838	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		72,279	September 2024	September 2018 Public Offering
	Grand Total		432,142

Schedule of Warrants Activity

A summary of warrant activity was as follows (In thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2018		944,635		$	22.50		5.87	$	-
Issued		31,885,500			-
Exercised *		(31,540,962	)		-
Exchanged		(856,865	)		0.37
Expired		(166	)		56.25
Outstanding and exercisable warrants at October 31, 2019		432,142		$	0.08		4.76	$	114,069
Issued		5,000,000			1.25
Exercised **		(33,916	)		0.02
Exchanged		(5,000,000	)		1.25
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640

* Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.

** Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

Schedule of Assumptions Used in Warrant Liability

In measuring the warrant liability, the Company used the following inputs in its Monte Carlo simulation model:

	October 31, 2020			October 31, 2019
Exercise Price	$	0.37		$	0.37
Stock Price	$	0.34		$	0.32
Expected Term		3.87 years			4.87 years
Volatility %		105.58	%		100.99	%
Risk Free Rate		0.29	%		1.51	%

Share Based Compensation (Tables)

12 Months Ended

Oct. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of Share Based Compensation Expense

The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2020 and 2019 (in thousands):

	Year Ended October 31,
	2020		2019
Research and development	$	308	$	1,036
General and administrative		583		966
Total	$	891	$	2,002

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the fiscal year ended October 31, 2020 and 2019 is as follows:

	Number of RSU’s			Weighted-Average Grant Date Fair Value
Unvested as of October 31, 2018		32,614		$	70.41
Vested		(12,257	)		78.41
Cancelled		(5,651	)		112.39
Unvested as of October 31, 2019		14,706		$	47.62
Vested		(8,870	)		60.59
Cancelled		(280	)		98.80
Unvested as of October 31, 2020		5,556		$	24.32

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the years ended October 31, 2020 and 2019 is as follows (in thousands, except share and per share data):

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2018		330,071		$	122.79		6.56	$	-
Granted		265,882			2.36
Cancelled or expired		(35,463	)		29.52
Outstanding as of October 31, 2019		560,490		$	71.56		7.34	$	1
Granted		645,000			0.61
Cancelled or expired		(193,722	)		34.47
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Vested and exercisable at October 31, 2020		307,467		$	105.69		4.91	$	1

Summary of Outstanding and Exercisable Options

The following table summarizes information about the outstanding and exercisable options at October 31, 2020:

Options Outstanding										Options Exercisable
				Weighted		Weighted						Weighted		Weighted
				Average		Average						Average		Average
Exercise		Number		Remaining		Exercise		Intrinsic		Number		Remaining		Exercise		Intrinsic
Price Range		Outstanding		Contractual		Price		Value		Exercisable		Contractual		Price		Value
$	.30-$10.00		746,579		9.41	$	1.10	$	1		68,655		8.67	$	2.62	$	-
$	10.01-$100.00		102,951		7.23	$	28.77	$	-		76,574		7.16	$	29.67	$	-
$	100.01-$200.00		92,847		2.76	$	166.04	$	-		92,847		2.76	$	166.04	$	-
$	200.01-$277.50		69,391		1.58	$	210.79	$	-		69,391		1.58	$	210.79	$	-

Summary of Fair Value of Stock Options Granted of BSM

The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model:

	Year Ended
	October 31, 2020			October 31, 2019
Expected term	5.50-6.50 years			5.50-6.51 years
Expected volatility		100.27-105.21	%		90.24-104.99	%
Expected dividends		0	%		0	%
Risk free interest rate		0.36-0.62	%		1.35-3.15	%

Leases (Tables)

12 Months Ended

Oct. 31, 2020

Leases [Abstract]

Schedule of Supplemental Balance Sheet Related to Leases

Supplemental balance sheet information related to leases as of October 31, 2020 was as follows (in thousands):

Operating Leases:
Operating lease right-of-use assets	$	4,839

Operating lease liability	$	962
Operating lease liability, net of current portion		5,055
Total operating lease liabilities	$	6,017

Schedule of Lease Expenses

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Year Months Ended October 31, 2020
Operating lease cost	General and administrative	$	1,158
Short-term lease cost	General and administrative		320
Variable lease cost	General and administrative		547
Total lease expense		$	2,025

Schedule of Other Information Related to Leases

Other information related to leases where the Company is the lessee is as follows:

For the Fiscal Year

Ended
October 31, 2020

Weighted-average remaining lease term

5.1 years

Weighted-average discount rate

6.5

Schedule of Cash Flow Information Related to Leases

Supplemental cash flow information related to operating leases was as follows:

For the Fiscal Year

Ended
October 31, 2020

Cash paid for operating lease liabilities

1,233

Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases

Future minimum lease payments under non-cancellable leases as of October 31, 2020 were as follows:

Fiscal Year ending October 31,
2021	$	1,318
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total minimum lease payments		7,065
Less: Imputed interest		(1,048	)
Total	$	6,017

Schedule of Future Minimum Payments Under Operating Lease

Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands):

Fiscal Year ending October 31,
2021	$	1,318
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total	$	7,065

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provision (Benefit)

The income tax provision (benefit) consists of the following (in thousands):

	October 31, 2020			October 31, 2019
Federal
Current	$	-		$	-
Deferred		(4,578	)		32,673
State and Local
Current		-			-
Deferred		(1,445	)		(1,634	)
Change in valuation allowance		6,023			(31,039	)
Income tax provision (benefit)	$	-		$	-

Schedule of Deferred Tax Assets (Liabilities)

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands):

	Years Ended
	October 31, 2020			October 31, 2019
Deferred Tax Assets
Net operating loss carryovers	$	28,553		$	22,627
Stock-based compensation		10,132			11,767
Research and development credits		10,742			10,234
Capitalized R&D costs		13,822			13,399
Deferred revenue		-			-
Adoption of ASC 842 – Lease Liability		1,691			-
Other deferred tax assets		224			405
Total deferred tax assets	$	65,164		$	58,432
Valuation allowance		(62,845	)		(56,822	)
Deferred tax asset, net of valuation allowance	$	2,319		$	1,610

Deferred Tax Liabilities
Adoption of ASC 842 – ROU Asset		(1,360	)		-
Patent Cost		(917	)		-
Other deferred tax liabilities		(42	)		(1,610	)
Total deferred tax liabilities	$	(2,319	)	$	(1,610	)
Net deferred tax asset (liability)	$	-		$	-

Schedule of Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2020			October 31, 2019
US Federal statutory rate		21.00	%		21.00	%
State income tax, net of federal benefit		5.48			9.84
Permanent differences		(0.05	)		1.23
Research and development credits		1.73			17.30
Change in valuation allowance		(22.82	)		186.84
§382 Impact on NOL		-			(233.87	)
Stock Option Expirations		(5.33	)		(2.34	)
Income tax (provision) benefit		0.00	%		0.00	%

Fair Value (Tables)

12 Months Ended

Oct. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2020 and October 31, 2019:

October 31, 2020	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	17	$	17

October 31, 2019		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024			-				-			$	19			$	19

Schedule of Changes in Fair Value of Warrant Liabilities

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities:

	Year Ended October 31,
	2020			2019
Beginning balance	$	19		$	6,517
Shares issued in settlement of warrants		-			(3,856	)
Warrant exercises		(2	)		(53	)
Change in fair value		-			(2,589	)
Ending Balance	$	17		$	19

Nature of Operations and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	1 Months Ended				6 Months Ended	12 Months Ended		84 Months Ended
	May 31, 2020	Jan. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from public offering	$ 40,000	$ 9,600	$ 15,500	$ 17,000	$ 1,583	$ 17,200		$ 309,400
Cash and cash equivalents			$ 32,363		$ 25,178	25,178	$ 32,363	$ 25,178
Operating expenses						$ 26,702	$ 38,856

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Nov. 02, 2019
Concentration at credit risk	$ 24,100
Number of securities included in computation of basic earnings per share	1,415,550	1,007,338
Exercise price	$ 0
Operating lease liability	$ 962
Right to use asset	$ 4,839
ASC 842 [Member]
Operating lease liability			$ 6,800
Right to use asset			5,600
Accrued rent liability, current			900
Lease incentive obligation, current			$ 300
Warrants [Member]
Number of securities included in computation of basic earnings per share	327,338
Pre-Funded Warrants [Member]
Number of securities included in computation of basic earnings per share		13,079,000
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Estimated useful life of intangible assets	3 years
Maximum [Member]
Estimated useful lives of property and equipment	10 years
Estimated useful life of intangible assets	20 years

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Total	1,415,550	1,007,338
Warrants [Member]
Total	398,226	432,142
Stock Options [Member]
Total	1,011,768	560,490
Restricted Stock Units [Member]
Total	5,556	14,706

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Depreciation expense	$ 897	$ 1,097
Laboratory Equipment [Member]
Loss on disposal of asset	0	300
Impairment loss on idle laboratory equipment	$ 1,100	$ 900

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,335
Laboratory equipment	1,218	3,405
Furniture and fixtures	744	744
Computer equipment	409	409
Construction in progress	19	83
Total property and equipment	4,725	6,976
Accumulated depreciation and amortization	(2,332)	(2,626)
Net property and equipment	$ 2,393	$ 4,350

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Expiration of patents description	The expirations of the existing patents range from 2020 to 2040
Book value patent applications, net	$ 1,725	$ 1,104
Intangible asset amortization expense	$ 337	$ 386

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,479	$ 5,833
License	777	777
Software	117	117
Total intangibles	5,373	6,727
Accumulated amortization	(2,112)	(2,152)
Intangible assets	$ 3,261	$ 4,575

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Oct. 31, 2020 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 289
2022	289
2023	289
2024	289
2025	289
Thereafter	1,816
Total	$ 3,261

Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Payables and Accruals [Abstract]
Salaries and other compensation	$ 737	$ 158
Vendors	671	3,194
Professional fees	329	126
Total accrued expenses	$ 1,737	$ 3,478

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) $ / shares in Units, $ in Thousands			12 Months Ended
	Oct. 16, 2020 $ / shares shares	Mar. 14, 2019 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares shares	Oct. 31, 2019 USD ($) $ / shares shares	May 31, 2020 $ / shares	Jul. 31, 2019 shares
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares			398,226	432,142
Warrant exercise price per share			$ 0.372	$ 0.372	$ 0.64
Loss on shares issued in settlement of warrants \| $			$ (77)	$ (1,607)
Fair value of the warrant liability \| $			17	19
Income on fair value of warrants \| $			$ 0	$ 2,600
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	1.25	22.50
Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.406	6.45
Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	4 years 9 months 3 days	5 years 6 months
Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input fair value, percentage	101.18%	96.37%
Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input fair value, percentage	0.32%	2.44%
Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares	5,000,000	856,865
Warrant exercise price per share	$ 1.25	$ 22.50
Warrant expiration	Jul. 21, 2025	Sep. 11, 2024
Loss on shares issued in settlement of warrants \| $		$ 1,600
Private Exchange Agreement [Member] \| Investor [Member]
Class of Warrant or Right [Line Items]
Number of common stock shares issued \| shares	3,000,000	856,865
Fair value of warrant \| $		$ 3,900
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares			327,363	359,863
Warrants outstanding \| shares			398,226	432,142
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares			70,863	72,279
Warrants outstanding \| shares			398,226	432,142
Income on fair value of warrants \| $				$ (2,589)
Warrant Liability [Member] \| Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share			$ 0.37	$ 0.37
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term			3 years 10 months 14 days	4 years 10 months 14 days
Warrant Liability [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input			105.58	100.99
Warrant Liability [Member] \| Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input			0.29	1.51
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share			$ 0	$ 0
Minimum [Member] \| Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share		$ 4.50
Minimum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share			0.372
Maximum [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock \| shares						17,142,000
Warrant exercise price per share			281.25	$ 281.25
Maximum [Member] \| Private Exchange Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share		$ 22.50
Maximum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share			$ 22.50

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	May 31, 2020
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372	$ 0.64
Number of Shares Underlying Warrants	398,226	432,142
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price
Number of Shares Underlying Warrants	327,338	359,838
Expiration Date	Jul. 31, 2024	Jul. 31, 2024
Summary of Warrants	July 2019 Public Offering	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25	$ 281.25
Number of Shares Underlying Warrants	25	25
Summary of Warrants	Other Warrants	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	70,863	72,279
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Summary of Warrants	September 2018 Public Offering	September 2018 Public Offering

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

Oct. 31, 2020

Oct. 31, 2019

Common Stock Purchase Warrants And Warrant Liability

Number of Warrants, Outstanding and exercisable warrants, Beginning balance

432,142

944,635

Number of Warrants, Issued

5,000,000

31,885,500

Number of Warrants, Exercised

^[1]

(33,916)

^[2]

(31,540,962)

Number of Warrants, Exchanged

(5,000,000)

(856,865)

Number of Warrants, Expired

(166)

Number of Warrants, Outstanding and exercisable warrants, Ending balance

398,226

432,142

Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning

$ 0.08

$ 22.50

Weighted Average Exercise Price, Issued

1.25

Weighted Average Exercise Price, Exercised

^[1]

0.02

^[2]

Weighted Average Exercise Price, Exchanged

1.25

0.37

Weighted Average Exercise Price, Expired

56.25

Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending

$ 0.08

Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning

4 years 9 months 3 days

56 years 2 months 30 days

Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance

3 years 9 months 3 days

4 years 9 months 3 days

Aggregate Intrinsic Value, Beginning

$ 114,069

Aggregate Intrinsic Value, Ending

$ 110,640

$ 114,069

[1]	Includes the cashless exercise of 17,869,662 warrants that resulted in the issuance of 17,869,662 shares of common stock.
[2]	Includes the cashless exercise of 32,500 warrants that resulted in the issuance of 32,500 shares of common stock.

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical) - shares	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Cashless warrant exercise	32,500	17,869,662
Warrants [Member]
Number of common stock shares issued	32,500	17,869,662

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Oct. 31, 2020 $ / shares	Oct. 16, 2020 $ / shares	May 31, 2020 $ / shares	Oct. 31, 2019 $ / shares	Mar. 14, 2019 $ / shares
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372		$ 0.64	$ 0.372
Stock Price	0
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage		1.25			22.50
Stock Price [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage		0.406			6.45
Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term		4 years 9 months 3 days			5 years 6 months
Warrant Liability [Member] \| Exercise Price [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.37			0.37
Warrant Liability [Member] \| Stock Price [Member]
Class of Warrant or Right [Line Items]
Stock Price	$ 0.34			$ 0.32
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	3 years 10 months 14 days			4 years 10 months 14 days
Warrant Liability [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	105.58			100.99
Warrant Liability [Member] \| Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.29			1.51

Share Based Compensation (Details Narrative) - USD ($) $ in Thousands			12 Months Ended
	Mar. 29, 2019	Mar. 21, 2018	Oct. 31, 2020	Oct. 31, 2019	May 04, 2020	Jan. 02, 2020	Feb. 21, 2019
Common stock authorized for issuance			170,000,000	170,000,000
Reverse stock split, description	1 for 15 reverse stock split
Unrecognized compensation cost related to non-vested stock option awards			$ 600
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 6 months
Stock compensation expense			$ 891	$ 2,002
Compensation cost related to outstanding stock options			$ 700	$ 1,200
Number of options, granted			645,000	265,882
Fair value of option granted			$ 300	$ 500
Expenses recorded under employee stock purchase plan			7	20
Restricted Stock Units (RSUs) [Member]
Fair value of equity purchases value			5	$ 51
Unrecognized compensation cost related to non-vested stock option awards			$ 64
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			5 months 20 days
Aggregate intrinsic value of non-vested RSU			$ 2
Employee Stock Awards [Member]
Share-based compensation, common stock, shares			8,870	12,245
Stock compensation expense			$ 200	$ 800
Maximum [Member]
Common stock authorized for issuance							170,000,000
Minimum [Member]
Common stock authorized for issuance							95,000,000
2015 Plan [Member]
Common stock reserved for issuance under plan			4,856,116			166,667
2015 Plan [Member] \| Maximum [Member]
Common stock authorized for issuance					6,000,000
2015 Plan [Member] \| Minimum [Member]
Common stock authorized for issuance					877,744
2018 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan		1,000,000
Discount price percentage		15.00%
Employee stock purchase plan description		The Company's shareholders on March 21, 2018. The 2018 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2018 ESPP beginning May 1, 2018. 1,000,000 shares of the Company's Common stock are reserved for issuance under the 2018 ESPP.
2018 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan			976,517
Number of shares issued under employee stock purchase plan			14,148	7,435
Expenses recorded under employee stock purchase plan			$ 1	$ 2
Stock Split [Member] \| 2015 Plan [Member]
Issuance of common stock			240,000
Stock Split [Member] \| 2015 Plan [Member] \| Maximum [Member]
Issuance of common stock			43,333

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Share-based compensation expense	$ 891	$ 2,002
Research and Development [Member]
Share-based compensation expense	308	1,036
General and Administrative [Member]
Share-based compensation expense	$ 583	$ 966

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Number of RSUs, Unvested Beginning Balance	14,706	32,614
Number of RSUs, Vested	(8,870)	(12,257)
Number of RSUs, Cancelled	(280)	(5,651)
Number of RSUs, Unvested Ending Balance	5,556	14,706
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance	$ 47.62	$ 70.41
Weighted-Average Grant Date Fair Value, Vested	60.59	78.41
Weighted-Average Grant Date Fair Value, Cancelled	98.80	112.39
Weighted-Average Grant Date Fair Value, Unvested Ending Balance	$ 24.32	$ 47.62

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance	560,490	330,071
Shares, Granted	645,000	265,882
Shares, Cancelled or Expired	(193,722)	(35,463)
Shares Outstanding, Ending Balance	1,011,768	560,490
Shares, Vested and Exercisable	307,467
Weighted-Average Exercise Price, Outstanding, Beginning	$ 71.56	$ 122.79
Weighted-Average Exercise Price, Granted	0.61	2.36
Weighted-Average Exercise Price, Cancelled or Expired	34.47	29.52
Weighted-Average Exercise Price, Outstanding, Ending	33.43	$ 71.56
Weighted-Average Exercise Price, Vested and Exercisable	$ 105.69
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	7 years 4 months 2 days	6 years 6 months 21 days
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	8 years 15 days	7 years 4 months 2 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 10 months 28 days
Aggregate Intrinsic Value, Beginning	$ 1
Aggregate Intrinsic Value, Ending	4	$ 1
Aggregate Intrinsic Value, Vested and Exercisable	$ 1

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2018
Options Outstanding, Number Outstanding	1,011,768	560,490	330,071
Options Weighted Average Remaining Contractual	7 years 4 months 2 days	6 years 6 months 21 days
Options Outstanding, Weighted Average Exercise Price	$ 33.43	$ 71.56	$ 122.79
Options Outstanding, Intrinsic Value	$ 4	$ 1
Options Exercisable, Number Outstanding	307,467
Options Exercisable, Weighted Average Exercise Price	$ 105.69
Options Exercisable, Intrinsic Value	$ 1
Exercise Price Range One [Member]
Range, lower limit	$ 0.30
Range, upper limit	$ 10.00
Options Outstanding, Number Outstanding	746,579
Options Weighted Average Remaining Contractual	9 years 4 months 28 days
Options Outstanding, Weighted Average Exercise Price	$ 1.10
Options Outstanding, Intrinsic Value	$ 1
Options Exercisable, Number Outstanding	68,655
Options Weighted Average Remaining Contractual Term Exercisable	8 years 8 months 2 days
Options Exercisable, Weighted Average Exercise Price	$ 2.62
Options Exercisable, Intrinsic Value
Exercise Price Range Two [Member]
Range, lower limit	$ 10.01
Range, upper limit	$ 100.00
Options Outstanding, Number Outstanding	102,951
Options Weighted Average Remaining Contractual	7 years 2 months 23 days
Options Outstanding, Weighted Average Exercise Price	$ 28.77
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	76,574
Options Weighted Average Remaining Contractual Term Exercisable	7 years 1 month 27 days
Options Exercisable, Weighted Average Exercise Price	$ 29.67
Options Exercisable, Intrinsic Value
Exercise Price Range Three [Member]
Range, lower limit	$ 100.01
Range, upper limit	$ 200.00
Options Outstanding, Number Outstanding	92,847
Options Weighted Average Remaining Contractual	2 years 9 months 3 days
Options Outstanding, Weighted Average Exercise Price	$ 166.04
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	92,847
Options Weighted Average Remaining Contractual Term Exercisable	2 years 9 months 3 days
Options Exercisable, Weighted Average Exercise Price	$ 166.04
Options Exercisable, Intrinsic Value
Exercise Price Range Four [Member]
Range, lower limit	$ 200.01
Range, upper limit	$ 277.50
Options Outstanding, Number Outstanding	69,391
Options Weighted Average Remaining Contractual	1 year 6 months 29 days
Options Outstanding, Weighted Average Exercise Price	$ 210.79
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	69,391
Options Weighted Average Remaining Contractual Term Exercisable	1 year 6 months 29 days
Options Exercisable, Weighted Average Exercise Price	$ 210.79
Options Exercisable, Intrinsic Value

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Expected Dividends	0.00%	0.00%
Minimum [Member]
Expected Term	5 years 6 months	5 years 6 months
Expected Volatility	100.27%	90.24%
Risk Free Interest Rate	0.36%	1.35%
Maximum [Member]
Expected Term	6 years 6 months	6 years 6 months 3 days
Expected Volatility	105.21%	104.99%
Risk Free Interest Rate	0.62%	3.15%

Collaboration and Licensing Agreements (Details Narrative) - USD ($)						3 Months Ended	12 Months Ended
	Feb. 08, 2019	Dec. 10, 2018	Sep. 04, 2018	Aug. 02, 2016	Mar. 19, 2014	Apr. 30, 2020	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2014
Revenue							$ 253,000	$ 20,884,000
Deferred revenue							165,000
Value of stock purchased							9,628,000	24,471,000
License and Service [Member] \| Global BioPharma, Inc [Member]
Revenue							250,000	250,000
Merck Agreement [Member]
Agreement expenses							900,000	900,000
OS Therapies [Member]
Deferred revenue							164,653
OS Therapies [Member] \| Within Five Business Days [Member]
Funding milestone payment			$ 2,337,500
Non-refundable and non-creditable payment			1,550,000
Upfront fees, amount			1,550,000
OS Therapies [Member] \| Creditable [Member]
Funding milestone payment			25,000
Non-refundable and non-creditable payment			$ 1,550,000
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Revenue						$ 25,000
Funding milestone payment						$ 2,337,500
Amgen Agreement [Member]
Revenue							0	20,600,000
Deferred revenue		$ 18,200,000
Upfront payment				$ 40,000,000
Number of common stock shares issued				203,163
Share issued price per share				$ 123.00
Value of stock purchased				$ 25,000,000
Development, regulatory and sales milestone payments				475,000,000
Upfront payment recorded as deferred revenue		40,000,000		$ 40,000,000
Cumulative catch-up revenue	$ 2,600,000	$ 15,600,000
Reduction in research and development expenses							0	2,000,000
Aratana Agreement [Member]
Upfront payment					$ 1,000,000
Development, regulatory and sales milestone payments					36,500,000
Licensing revenue									$ 1,000,000
Additional, cumulative sales milestone payments					$ 15,000,000
Aratana Agreement [Member] \| Royalty [Member]
Revenue							$ 3,000	$ 8,000

Commitments and Contingencies (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Thousands	Sep. 19, 2018 USD ($)
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Leases (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
Leases (Details Narrative) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Leases [Abstract]
Operating lease expiration	Nov. 30, 2025
Security deposit	$ 182
Rent expense		$ 1,200

Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 4,839
Operating lease liability	962
Operating lease liability, net of current portion	5,055
Total operating lease liabilities	$ 6,017

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] $ in Thousands	12 Months Ended
	Oct. 31, 2020 USD ($)
Operating lease cost	$ 1,158
Short-term lease cost	320
Variable lease cost	547
Total lease expense	$ 2,025

Leases - Schedule of Other Information Related to Leases (Details)	Oct. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	5 years 1 month 6 days
Weighted-average discount rate	6.50%

Leases - Schedule of Cash Flow Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Oct. 31, 2020 USD ($)
Leases [Abstract]
Cash paid for operating lease liabilities	$ 1,233

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) $ in Thousands	Oct. 31, 2020 USD ($)
Leases [Abstract]
2021	$ 1,318
2022	1,369
2023	1,395
2024	1,419
2025	1,444
Thereafter	120
Total minimum lease payments	7,065
Less: Imputed interest	(1,048)
Total	$ 6,017

Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) $ in Thousands	Oct. 31, 2020 USD ($)
Leases [Abstract]
2021	$ 1,318
2022	1,369
2023	1,395
2024	1,419
2025	1,444
Thereafter	120
Total	$ 7,065

Income Taxes (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Net operating loss carry-forward	$ 89,400	$ 74,000
Operating loss expiration year	2023
Income tax reconciliation description	NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations.
Total net operating loss carry-forward	$ 299,200
Net operating loss and deferred tax asset does not include nol's	209,800
New jersey state net operating loss carryovers	137,700
Interest or penalties on unpaid tax
Income tax expense	50	$ 50
Internal Revenue Code [Member]
Net operating loss carry-forward	$ 89,400
GPP Revenue [Member]
Income tax reconciliation description	This is a Taiwan Excise tax of 50 levied in connection with the GPP Revenue.

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Federal Current
Federal Deferred	(4,578)	32,673
State and Local Current
State and Local Deferred	(1,445)	(1,634)
Change in valuation allowance	6,023	(31,039)
Income tax provision (benefit)

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 28,553	$ 22,627
Stock-based compensation	10,132	11,767
Research and development credits	10,742	10,234
Capitalized R&D costs	13,822	13,399
Deferred revenue
Adoption of ASC 842 - Lease Liability	1,691
Other deferred tax assets	224	405
Total deferred tax assets	65,164	58,432
Valuation allowance	(62,845)	(56,822)
Deferred tax asset, net of valuation allowance	2,319	1,610
Adoption of ASC 842 - ROU Asset	(1,360)
Patent Cost	(917)
Other deferred tax liabilities	(42)	(1,610)
Total deferred tax liabilities	(2,319)	(1,610)
Net deferred tax asset (liability)

Income Taxes - Schedule of Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Income Tax Disclosure [Abstract]
US Federal statutory rate	21.00%	21.00%
State income tax, net of federal benefit	5.48%	9.84%
Permanent differences	(0.05%)	1.23%
Research and development credits	1.73%	17.30%
Change in valuation allowance	(22.82%)	186.84%
382 Impact on NOL	0.00%	(233.87%)
Stock Option Expirations	(5.33%)	(2.34%)
Income tax (provision) benefit	0.00%	0.00%

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended					3 Months Ended	6 Months Ended	12 Months Ended		84 Months Ended
	Jul. 30, 2020	May 31, 2020	Jan. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Jul. 31, 2020	Feb. 21, 2019
Proceeds from sale of common shares								$ 2,489,104
Pre-funded warrants to purchase common shares					13,656,000
Number of warrants to purchase common stock				432,142			398,226	398,226	398,226	432,142	398,226
Net proceeds from offering		$ 40,000	$ 9,600	$ 15,500	$ 17,000			$ 1,583	$ 17,200		$ 309,400
Warrant description					Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.70, and each pre-funded warrant was sold together in a fixed combination with a warrant to purchase 0.75 shares of common stock for $0.699. The pre-funded warrants are exercisable immediately, do not expire and have an exercise price of $0.001 per share. The warrants are exercisable immediately, expire five years from the date of issuance, have an exercise price of $2.80 per share and are subject to anti-dilution and other adjustments for certain stock splits, stock dividends, or recapitalizations. The warrants also provide that if during the period of time between the date that is the earlier of (i) 30 days after issuance and (ii) if the common stock trades an aggregate of more than 35,000,000 shares after the pricing of the offering, and ending 15 months after issuance, the weighted-average price of common stock immediately prior to the exercise date is lower than the then-applicable exercise price per share, each Common Warrant may be exercised, at the option of the holder, on a cashless basis for one share of Common Stock. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $15.5 million.
Warrants exercise price		$ 0.64		$ 0.372			$ 0.372	$ 0.372	$ 0.372	$ 0.372	$ 0.372
Common stock, shares authorized				170,000,000			170,000,000	170,000,000	170,000,000	170,000,000	170,000,000
Number of common stock values									$ 9,628	$ 24,471
Gross proceeds from common stock									$ 15,496	$ 24,471
Lincoln Park Capital Fund, LLC [Member]
Number of common stock purchased							11,242,048
Gross proceeds from common stock							$ 5,100
Proceeds from netted legal fees							$ 50
Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Share price per share	$ 0.10
Net proceeds from offering	$ 1,000
Common stock, shares authorized	20,000
Agreement description	Over the 36-month term of the Purchase Agreement, up to an aggregate amount of $20,000,000 (subject to certain limitations) of shares of Common Stock, the Company has the right, but not the obligation, from time to time, in its sole discretion and subject to certain conditions, including that the closing price of its common stock is not below $0.10 per share, to direct Lincoln Park to purchase up to 1,000,000 shares (the "Regular Purchase Share Limit") of its Common Stock (each such purchase, a "Regular Purchase"). Lincoln Park's maximum obligation under any single Regular Purchase will not exceed $1,000,000, unless the parties mutually agree to increase the maximum amount of such Regular Purchase. The purchase price for shares of Common Stock to be purchased by Lincoln Park under a Regular Purchase will be the equal to the lower of (in each case, subject to the adjustments described in the Purchase Agreement): (i) the lowest sale price for the Company's common stock on the applicable purchase date, and (ii) the arithmetic average of the three lowest sale prices for the Company's common stock during the ten trading days prior to the purchase date.
Number of common stock shares issued	1,084,266
Number of common stock values	$ 600
Pre-funded Warrants [Member]
Number of warrants to purchase common stock				1						1
Warrants exercise price				$ 0.75						$ 0.75
ATM Program [Member]
Net proceeds from offering		$ 1,531
Proceeds from commission		$ 52
Maximum [Member]
Number of warrants to purchase common stock					17,142,000
Warrants exercise price				$ 281.25			$ 281.25	$ 281.25	$ 281.25	$ 281.25	$ 281.25
Common stock, shares authorized													170,000,000
Maximum [Member] \| Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Number of warrants to purchase common stock	1,000,000
Public Offering [Member]
Number of common stock shares sold			10,000,000			2,500,000
Share price per share						$ 4.00						$ 1.05
Proceeds from sale of common shares			$ 10,500			$ 9,000
Pre-funded warrants to purchase common shares					10,650,000
Private Placement [Member]
Number of warrants to purchase common stock												5,000,000
Warrants exercise price												$ 1.25

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Oct. 31, 2020	Oct. 31, 2019
Common stock warrant liability, warrants exercisable	$ 17	$ 19
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 17	$ 19

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Oct. 31, 2020	May 31, 2020	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 0.64	$ 0.372

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Beginning balance	$ 19
Warrant exercises	2	$ 122
Change in fair value	0	2,600
Ending Balance	17	19
Warrant Liability [Member]
Beginning balance	19	6,517
Shares issued in settlement of warrants		(3,856)
Warrant exercises	(2)	(53)
Change in fair value		(2,589)
Ending Balance	$ 17	$ 19

Employee Benefit Plan (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
401(k) Plan [Member]
Employee contributions, amount	$ 100	$ 200

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended							3 Months Ended	6 Months Ended	12 Months Ended		84 Months Ended
	Jan. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	May 31, 2020	Jan. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Jan. 22, 2021	Oct. 31, 2020	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Jul. 31, 2020
Warrants exercise price				$ 0.64		$ 0.372			$ 0.372	$ 0.372	$ 0.372	$ 0.372
Net proceeds from public offering				$ 40,000	$ 9,600	$ 15,500	$ 17,000		$ 1,583	$ 17,200		$ 309,400
Warrants [Member]
Number of shares issued on public offering										32,500	17,869,662
Common Stock [Member]
Number of shares issued on public offering										10,000,000	13,150,000
Private Placement [Member]
Warrants exercise price													$ 1.25
Subsequent Event [Member]
Number of shares issued on public offering			30,666,665
Shares issued price per share			$ 0.30
Gross proceeds from public offering			$ 9,200
Warrants exercise price			$ 0.35
Net proceeds from public offering			$ 8,500
Subsequent Event [Member] \| OS Therapies LLC [Member] \| Milestone set forth in the Licence Agreement [Member]
Proceeds from milestone achievement	$ 1,345	$ 1,345
Milestone achievement, description	We received an aggregate of $1,345,000 from OS Therapies upon achievement of the $1,550,000 funding milestone set forth in the license agreement.	We received an aggregate of $1,345,000 from OS Therapies upon achievement of the $1,550,000 funding milestone set forth in the license agreement.
Subsequent Event [Member] \| Warrant Holders [Member] \| Warrants [Member]
Number warrants exercised during period								4,610,000
Proceeds from warrants								$ 1,600
Subsequent Event [Member] \| Warrant Holders [Member] \| Common Stock [Member]
Number of common stock exchanged for warrants								4,610,000
Subsequent Event [Member] \| Private Placement [Member]
Number of warrants to purchase shares of common stock			15,333,332